Although we propose that targeted delivery of siRNA via exosomes derived from primary tumor cells of BRCA patients can effectively suppress the expression of TMEM45A in tumor cells, this method has not yet been translated and validated in clinical settings and thus has certain limitations. The gene discussed is TMEM45A; the disease is neoplasm.